Drugs / SAD448
Trials 1
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 1 | NCT00503360 | Apr 2007 → ? | ocular hypertension | Novartis | Completed | No outcome recorded |
Evidence & citations 5 cited values
Every value below carries the sentence it was read from. 2 sources stand behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | SAD448 | ClinicalTrials.gov intervention name — accepted as the source's own label NCT00503360 ↗ |
| Action | Activate | “Cannabinoid CB2 receptor agonist” CHEMBL2397751 ↗1“Cannabinoid CB1 receptor agonist” CHEMBL2397751 ↗ |
| Modality | Small molecule | — CHEMBL2397751 ↗ |
| Target | CNR1 | “Cannabinoid CB1 receptor agonist” CHEMBL2397751 ↗ |
| Target | CNR2 | “Cannabinoid CB2 receptor agonist” CHEMBL2397751 ↗ |